1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides an overview of the Ulcerative Colitis (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Ulcerative Colitis (Colitis ulcerosa or UC) is a chronic disease mainly of the large intestine or colon and a type of Inflammatory Bowel Disease (IBD). The disease is characterized by open sores and ulcers in the colon. The risk factors for UC include smoking, family history of the disease, liver disease, colon cancer, depression, and severe dehydration. Common symptoms of ulcerative colitis include rectal bleeding, abdominal pain, and diarrhea. Treatment options for ulcerative colitis include surgery (removal of colon) or drug therapy with aminoasylates (ASA), immunomodulators, and corticosteroids.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Ulcerative Colitis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Ulcerative Colitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Ulcerative Colitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Ulcerative Colitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 20, 51, 51, 3, 100, 30 and 1 respectively. Similarly, the Universities portfolio in Phase 0 and Preclinical stages comprises 1 and 11 molecules, respectively.
Ulcerative Colitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Ulcerative Colitis (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Ulcerative Colitis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Ulcerative Colitis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Ulcerative Colitis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Ulcerative Colitis (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Ulcerative Colitis (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Ulcerative Colitis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Ulcerative Colitis - Overview
- Ulcerative Colitis - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Ulcerative Colitis - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Ulcerative Colitis - Companies Involved in Therapeutics Development
- Ulcerative Colitis - Drug Profiles
- Ulcerative Colitis - Dormant Projects
- Ulcerative Colitis - Discontinued Products
- Ulcerative Colitis - Product Development Milestones
- Featured News & Press Releases
- Jul 27, 2022: EC grants approval for AbbVie’s Rinvoq to treat ulcerative colitis in adults
- Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
- Jul 18, 2022: Prometheus Biosciences completes enrollment of the ARTEMIS-UC cohort 1 phase 2 study in ulcerative colitis
- Jul 07, 2022: Biora Therapeutics announces successful completion of second device performance study in human subjects for its targeted therapeutics platform
- Jul 06, 2022: Applied Molecular Transport announces top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
- Jul 06, 2022: Applied Molecular Transport to report top-line phase 2 results from MARKET combination trial of oral AMT-101 in patients with moderate-to-severe ulcerative colitis
- Jul 04, 2022: Innovent Phase II ulcerative colitis antibody trial doses first subject
- Jun 20, 2022: EMA accepts Sandoz’s application for high concentration of biosimilar
- Jun 08, 2022: Prometheus Biosciences provides enrollment update in APOLLO-CD and ARTEMIS-UC global phase 2 Studies
- May 31, 2022: Biora Therapeutics shares presentation of patient data establishing correlation between drug levels in colon and patient outcomes in ulcerative colitis
- May 27, 2022: The lancet publishes results from phase 3 induction and maintenance programs evaluating Upadacitinib (RINVOQ) in ulcerative colitis
- May 24, 2022: InDex Pharmaceuticals to exhibit at Digestive Disease Week
- May 24, 2022: Pfizer presents ELEVATE pivotal findings demonstrating etrasimod’s potentially best-in-class profile in ulcerative colitis
- May 24, 2022: Fifty percent of patients with ulcerative colitis treated with Mirikizumab achieved clinical remission at one year in Lilly's pivotal phase 3 study
- May 24, 2022: Alvotech clinical study results demonstrate therapeutic equivalence between biosimilar candidate AVT04 and reference product Stelara
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
List of Tables
- Number of Products under Development for Ulcerative Colitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Ulcerative Colitis - Dormant Projects, 2022
- Ulcerative Colitis - Discontinued Products, 2022
List of Figures
- Number of Products under Development for Ulcerative Colitis, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 180 Life Sciences Corp
- 9 Meters Biopharma Inc
- AbbVie Inc
- Abivax SA
- Accro Bioscience Suzhou Co Ltd
- Aclaris Therapeutics Inc
- Adiso Therapeutics Inc
- Affilogic SAS
- Akebia Therapeutics Inc
- Akeso Inc
- Algernon Pharmaceuticals Inc
- Alpha Cancer Technologies Inc
- AltruBio Inc
- Alvotech ehf
- Am-Pharma BV
- Amgen Inc
- Amide Technologies Inc
- Applied Molecular Transport Inc
- Aqilion AB
- Aravive Inc
- Artelo Biosciences Inc
- Artizan Biosciences Inc
- Asieris Pharmaceuticals Co Ltd
- Asta Pharmaceuticals Co Ltd
- AstraZeneca Plc
- Atlantic Healthcare Plc
- Avesthagen Ltd
- Avexegen Therapeutics Inc
- Azora Therapeutics Australia Pty Ltd
- BenevolentAI Ltd
- Bilix Co Ltd
- Bio-Thera Solutions Ltd
- Biocon Ltd
- BioGaia AB
- Biohaven Pharmaceutical Holding Company Ltd
- Biora Therapeutics Inc
- BioXpress Therapeutics SA
- Boehringer Ingelheim International GmbH
- Bridge Biotherapeutics Inc
- Bristol-Myers Squibb Co
- Captor Therapeutics SA
- Cellix Bio Pvt Ltd
- Celltrion Inc
- Chain Biotechnology Ltd
- ChemoCentryx Inc
- Chengdu Jinrui Foundation Biotechnology Co Ltd
- Chong Kun Dang Holdings Corp
- ChunLab Inc
- Circle33 LLC
- Claritas Pharmaceuticals Inc
- ClostraBio Inc
- Cloud Pharmaceuticals Inc
- Comera Life Sciences Inc
- Cosmo Pharmaceuticals NV
- Cristcot HCA LLC
- Cureveda LLC
- Dadang & BIO Co Ltd
- Denali Therapeutics Inc
- DeNovX LLC
- Devonian Health Group Inc
- Direct Biologics LLC
- DM Bio Ltd
- DNX Biopharmaceuticals Inc
- Dr. August Wolff GmbH & Co KG Arzneimittel
- Eli Lilly and Co
- enGene Inc
- Ensign Pharmaceutical Inc
- Exeliom Biosciences SAS
- F. Hoffmann-La Roche Ltd
- Ferring International Center SA
- First Wave BioPharma Inc
- Formycon AG
- Fzata Inc
- Galapagos NV
- Galmed Pharmaceuticals Ltd
- Genentech USA Inc
- Genor BioPharma Co Ltd
- Giiant Pharma Inc
- Gossamer Bio Inc
- GSK plc
- Guangzhou Magpie Pharmaceutical Co Ltd
- Gusto Global LLC
- Han Wha Pharma Co Ltd
- Hangzhou Grand Biologic Pharmaceutical Inc
- Hefei Cosource Pharmaceutical Inc
- Hillhurst Biopharmaceuticals Inc
- Himuka AM Pharma Corp
- Holy Stone Healthcare Co Ltd
- Hoth Therapeutics Inc
- Huabo Biopharm (Shanghai) Co Ltd
- Ichnos Sciences Inc
- Iltoo Pharma
- Immix BioPharma Inc
- Immunic Inc
- Impetis Biosciences Ltd
- InDex Pharmaceuticals Holding AB
- Innovation Pharmaceuticals Inc
- Innovative Pharmacology Research
- Innovent Biologics Inc
- Innovimmune Biotherapeutics Inc
- Intact Therapeutics
- Intas Pharmaceuticals Ltd
- Intract Pharma Ltd
- Invea Therapeutics Inc
- Istesso Ltd
- Janux Therapeutics Inc
- Jiangsu Carephar Pharmaceutical Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- KD Pharma Group SA
- Kiniksa Pharmaceuticals Ltd
- KoBioLabs Inc
- Korea Pharma Co Ltd
- Koutif Therapeutics LLC
- Kyorin Pharmaceutical Co Ltd
- Landos Biopharma Inc
- LegoChem Biosciences Inc
- LG Chem Ltd
- LTT Bio-Pharma Co Ltd
- Lumen Bioscience Inc
- Lynk Pharmaceutical Hangzhou Co Ltd
- MAKScientific LLC
- Malachite Innovations Inc
- Merck & Co Inc
- Mesoblast Ltd
- Metacrine Inc
- Metagen Therapeutics Inc
- Microba Life Sciences Ltd
- Microbiotica Ltd
- Mitsubishi Tanabe Pharma Corp
- Morphic Therapeutic Inc
- MRM Health NV
- Nano Intelligent Biomedical Engineering Corp
- NeuClone Pty Ltd
- Nexbiome Therapeutics
- Nexel Co Ltd
- Novan Inc
- Novartis AG
- Novellus Therapeutics Ltd
- Novome Biotechnologies Inc
- Nubiyota LLC
- Numedii Inc
- Oncodesign SA
- Oncostellae SL
- Oryn Therapeutics
- OSE Immunotherapeutics SA
- Palatin Technologies Inc
- Palo BioFarma SL
- PanTheryx Inc
- Paradigm Biopharmaceuticals Ltd
- Parvus Therapeutics Inc
- Pfizer Inc
- Pharmabiome AG
- Pharmapraxis
- Pharmaxis Ltd
- PNB Vesper Life Science Pvt Ltd
- Praeventix LLC
- Prometheus Biosciences Inc
- Protab Ltd
- Protagonist Therapeutics Inc
- Protalix BioTherapeutics Inc
- Puretech Health Plc
- Qu Biologics Inc
- Rebiotix Inc
- Regentys Corp
- Reistone Biopharma Co Ltd
- RhemaStem SRLS
- Rhizen Pharmaceuticals SA
- Ribon Therapeutics Inc
- Salix Pharmaceuticals Ltd
- Samsung Bioepis Co Ltd
- Sandoz International GmbH
- Saniona AB
- Santhera Pharmaceuticals Holding AG
- Sareum Holdings Plc
- Semorex Technologies Ltd
- Senda Biosciences Inc
- Seres Therapeutics Inc
- Servatus Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Haishi Biopharmaceutical Co Ltd
- Shanghai Jiyu Pharmaceutical Technology Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shaperon Inc
- Siam Bioscience Co Ltd
- StemRIM Inc
- sterna biologicals Gmbh & Co KG
- Sublimity Therapeutics HoldCo Ltd
- Suono Bio Inc
- Surrozen Inc
- Suzhou Connect Biopharmaceuticals Ltd
- Suzhou Huyun New Drug Research and Development Co Ltd
- Synedgen Inc
- Synlogic Inc
- Takeda Pharmaceutical Co Ltd
- Tarus Therapeutics Inc
- TheraSource LLC
- Theravance Biopharma Inc
- Thetis Pharmaceuticals LLC
- Tianjin Hemay Pharmaceutical Co Ltd
- Tillotts Pharma AG
- Torrent Pharmaceuticals Ltd
- Vedanta Biosciences Inc
- Ventyx Biosciences Inc
- Vivreon Biosciences LLC
- Voronoi Group
- Zhiyi Pharmaceuticals Inc
